Compare Charles River Laboratories Intl. Inc (CRL) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Charles River Laboratories Intl. Inc trades at $285.69 (market cap $13.46B), while YieldMax Universe Fund of Option Income ETFs trades at $7.63. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| CRL | YMAX | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $282.00 | $13.26 |
52-Week Low | $145.57 | $7.27 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
YMAX trades at $7.63, down 1.04% today, with a bullish technical signal but bearish moving averages. The ETF maintains a consistent weekly dividend distribution schedule, though recent news highlights concerns about fee structures impacting payouts. Key resistance and support levels are clustered around $8, with the RSI indicating potential overbought conditions on a short-term basis.
The outlook is mixed; the fund's income strategy provides regular distributions, but high embedded costs and reliance on market volatility for returns present risks. Upside depends on favorable option-writing conditions, while downside is linked to market stability and expense drag.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
